Cancer Research

Though health care is free, it doesn't always come without a cost. The United Kingdom is behind most countries in lung cancer survival and the big reason is because it goes undiagnosed.

It isn't that people won't go to the doctor due to cost, so it must be that doctors don't pick up the signs of lung cancer and investigate them, say the authors of a new study who analyzed family doctors' (GPs') investigation of lung cancer between 2000 and 2013, using data from The Health Improvement Network (THIN), which contains the anonymized health records of millions of primary care patients across the UK.


Cancer-driving genomic aberrations in localized lung cancer appear are so consistently present across tumors that a single biopsy of one region of the tumor is likely to identify most of them, according to a new paper.

The study addresses the challenge of what scientists call genomic heterogeneity, the presence of many different variations that drive tumor formation, growth and progression, and likely complicate the choice and potential efficacy of therapy.

A landmark study of renal cell cancer in 2012 found that most cancer-promoting variations were not present across all regions of those tumors, so biopsy of a single region would not provide a good representation of cancer genes important in the genesis of any given tumor.


No matter what type of chemotherapy you attack a tumor with, many cancer cells resort to the same survival tactic: They start eating themselves. This autophagy process happens when two proteins pair up and switch it on this process, according to a new paper.

"This gives us a therapeutic avenue to target autophagy in tumors," says Brigham Young University chemistry professor Josh Andersen. "The idea would be to make tumors more chemo-sensitive. You could target these proteins and the mechanism of this switch to block autophagy, which would allow for lower doses of chemotherapy while hopefully improving patient outcomes."


It's not a movie about zombies, but it's a Halloween nightmare - at night while we sleep unaware, something deadly grows and spreads quickly.

In a surprise finding, Weizmann Institute of Science researchers have found that nighttime is the right time for cancer to grow and spread in the body. Their findings suggest that administering certain treatments in time with the body’s day-night cycle could boost their efficiency.
Researchers are investigating a possible association between breast implants and a form of lymphoma that may develop tumors at a later stage. The researchers conclude that breast implants can cause a new subtype of the rare yet malignant lymphoma known as anaplastic large cell lymphoma (ALCL).

Worldwide there have been 71 documented cases of patients with ALCL in which researchers suspected breast implants to be the cause. ALCL is normally found in the lymph nodes, as well as in skin, lung, liver and soft tissue, but not usually in the breast. 

A few years ago there was concern that poor people did not have access to the best health care because of high cost, but two new papers find that spending is actually too high.

The first study examines recent trends in spending and use of oral cancer drugs. They find that average spending on the 47 available oral oncolytics — cancer medication taken specifically by mouth — increased from $940 million in the first quarter of 2006 to $1.4 billion by the third quarter of 2011. 


A research group has discovered that AIM - Apoptosis Inhibitor of Macrophage - a protein that plays a preventive role in obesity progression, can also prevent tumor development in mice liver cells. 

This discovery may lead to a therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer and the third most common cause of cancer deaths.


Breast cancer is the second leading cause of cancer death in women, which is why so many medical professionals encourage women to get mammograms. But the tests are not very accurate: only a minority of suspicious mammograms actually leads to a cancer diagnosis.

Bad results lead to needless worry for women and their families—not to mention the time, discomfort and expense of additional tests, including ultrasounds and biopsies. 


Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces clinical trial findings showing that trastuzumab (Herceptin) should remain the standard of care for this cancer.


Rolapitant reduces nausea and vomiting in patients receiving cisplatin-based chemotherapy, according to the results of a phase III trial presented for the first time today at the ESMO 2014 Congress in Madrid, Spain.